CClinicalTrials.gg
CompletedNCT03754231Updated Mar 31, 2022

Validation Study on RENEW's Aingeal at KK Women's and Children's Hospital

An interventional study of Heart rate monitoring and Respiratory rate monitoring in Vital Sign, Heart Rate and Respiratory Rate, sponsored by KK Women's and Children's Hospital. Completed at 1 site in Singapore. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by KK Women's and Children's Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2018, registered Nov 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
3 Years to 17 Years
Sex
All
01

Study summary

This proposal describes the evaluation of a CE-marked, FDA cleared vital signs Surveillance Monitoring system in a paediatric outpatient population in KK Women's and Children's Hospital ("KKH"), the main tertiary women and children hospital in Singapore. User acceptance of Aingeal and the Surveillance System will be considered within the clinical settings.

Read the detailed description

RENEW's Surveillance Monitoring system is made up of two main components:

a patient-worn wireless vital signs monitor (Aingeal) that transmits data over Wi-Fi to a central station software platform (Surveillance Station). The Aingeal device measures single lead ECG, heart rate, respiration waveform and rate, and skin temperature. A snapshot of data is transmitted by the devices intermittently to the Surveillance Station, enabling vital signs trends to be plotted. This proposal describes the evaluation of RENEW's Aingeal device in a paediatric outpatient population in KK Women's and Children's Hospital ("KKH"), the main tertiary women and children hospital in Singapore. In the paediatric population, assessment of RENEW's Aingeal device will include the accuracy of the device at deriving heart rate from single lead ECG and at deriving respiratory rate when compared against a commonly used vital signs monitor. User acceptance of Aingeal and the Surveillance System will be considered within the clinical settings.

02

Conditions studied

  • Vital Sign
  • Heart Rate
  • Respiratory Rate

Keywords

  • Vital sign monitoring
  • Heart rate
  • Respiratory rate
03

In context

Lead sponsor

KK Women's and Children's Hospital is the lead sponsor of 136 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female paediatric patients, aged between 3 and 17 years
  • Patients attending outpatient care at KK Women's and Children's Hospital, Singapore

Exclusion criteria

Exclusion Criteria:

  • Patients with active, implantable devices (such as a pacemaker or ICD)
  • Patients with any skin condition or injury affecting the electrode placement site
  • Patients that are pregnant
  • Those patients who, in the opinion of the clinic staff, are not suitable to participate.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Aingeal

    All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.

    Other: Heart rate monitoring · Other: Respiratory rate monitoring

Interventions

  • OtherHeart rate monitoring

    The heart rate of recruited patients will be monitored for 15 minutes over 2 phases: i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing

  • OtherRespiratory rate monitoring

    The heart rate of recruited patients will be monitored for 15 minutes over 2 phases: i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing

06

What researchers measure

Primary outcomes

  1. Heart rate comparison

    Heart rate is calculated manually via ECG waveform and compared against the Aingeal device using Bland Altman approach

    Time frame: 15 minutes

Secondary outcomes

  1. Respiratory rate comparison

    Repiratory rate measurement is compared between Aingeal device and Capnostream device using Bland Altman approach.

    Time frame: 15 minutes

07

Study locations

1 site
  • KK Women's and Children's Hospital
    Singapore, 229899, Singapore
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 3, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03754231
Lead sponsor
KK Women's and Children's Hospital
Collaborators
Renew Group
Responsible party
Low Bao Bei Kelly (Associate Consultant, Department of Paediatrics, KK Women's and Children's Hospital) — Principal investigator
First posted
Nov 27, 2018
Start date
Jan 30, 2018
Primary completion
Dec 1, 2021
Completion
Dec 1, 2021
Last update
Mar 31, 2022

Study contacts

Bao Bei Kelly Low
principal investigator · KK Women's and Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion